CJC-1295 research monograph — the GHRH analog and the DAC question

CJC-1295 is one of the most-discussed growth-hormone-peptide compounds, and also
one where a single naming distinction — "with DAC" versus "without DAC" — causes
most of the confusion. This monograph clears that up.

Chemical identity & structure.
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), based
on a modified version of the first 29 amino acids of GHRH ("modified GRF 1-29").
The critical distinction:

• CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that

binds covalently to albumin in the bloodstream, dramatically extending the
half-life to a matter of days.

• CJC-1295 without DAC — frequently sold as "modified GRF 1-29" or "mod GRF

1-29" — lacks that group and has a very short half-life, on the order of
minutes.

These are pharmacologically very different compounds despite the shared name.

Mechanism of action.
Both forms are GHRH-receptor agonists: they act on the pituitary to stimulate
growth hormone release, the same pathway natural GHRH uses. Because they act
upstream — prompting the pituitary's own pulsatile release — their effect remains
subject to the body's regulatory feedback (including somatostatin). The DAC
versus non-DAC difference is almost entirely about duration of action, not
mechanism.

Key research findings.
Early clinical research on CJC-1295 with DAC documented sustained elevations in
GH and IGF-1 levels after administration. The literature is limited and mostly
from the compound's early development period; there is no large modern outcome-
trial program.

The research / citation base.
CJC-1295 is not an approved drug. Its evidence base is early clinical
pharmacology and preclinical research. It is reasonably well-characterized as to
how it raises GH/IGF-1, but not supported by large efficacy trials for any
specific health outcome.

Research protocols in the literature.
Research has used subcutaneous administration. The non-DAC form, with its short
half-life, is often studied in the context of pulse timing and is frequently
paired with a ghrelin-mimetic such as ipamorelin on the rationale of
complementary pathways; the DAC form is studied for its longer duration.

Quality & sourcing notes.
The single most important COA question for CJC-1295 is **which form the vial
contains** — with-DAC and without-DAC have different masses, and the COA's mass-
spectrometry result should match the form claimed on the label. Mislabeling
between the two forms is a known market problem.

*Research-use note: Educational summary of published research. CJC-1295 is not an
approved drug; this is research context only and not medical advice.*